Using artificial intelligence, followed by in vivo validation, this study identified the key cardiac mechanism of action of empagliflozin in heart failure in patients with or without diabetes mellitus.
SUMMARY
The mechanism of action of empagliflozin in heart failure with reduced ejection fraction (HFrEF) was deciphered using deep learning in silico analyses together with in vivo validation. The most robust mechanism of action involved the sodium-hydrogen exchanger (NHE)-1 co-transporter with 94.7% accuracy, which was similar for diabetics and nondiabetics. Notably, direct NHE1 blockade by empagliflozin ameliorated cardiomyocyte cell death by restoring expression of X-linked inhibitor of apoptosis (XIAP) and baculoviral IAP repeat-containing protein 5 (BIRC5). These results were independent of diabetes mellitus comorbidity, suggesting that empa- Moreover, empagliflozin pharmacological data and molecular relationships described for HF and DM were extracted by integrating massive, publicly available databases such as Drugbank, Reactome, MINT, and BioGrid. All this information accounted for more than 350,000 interactions ( Figure 1) . Briefly, by integrating published data, a set of molecular profiles characterizing HF and DM were defined, which were used to build the protein network and the mathematical model. See Supplemental Video 1. DM ¼ diabetes mellitus; GEO ¼ Gene Expression Omnibus database; HF ¼ heart failure; TPMS ¼ therapeutic performance mapping system.
Iborra-Egea et al. Table 1 ). This collection of experimental pathophysiological signals was used as a list of principles, termed a "truth table," which apply to a specific condition (i.e., some proteins are overexpressed only in HF patients with DM) ( Figure 1 ) and allow delineation of the molecular behavior of each situation (12) . The models are then able to weight the relative value of each protein (node) relationship.
T h e r a p e u t i c p e r f o r m a n c e m a p p i n g s y s t e m 
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DATA INTEGRATION AND STATISTICAL ANALYSIS.
The RNAseq data were compiled and processed using the GEO2R tool, using the neqc method for normali- 
Heart failure 106
Heart hypertrophy 33
Cardiomyocyte cell death 47
Inefficient myocardial fuel metabolism 7
Oxidative stress 8
Inflammation 11
Obesity 140
Hyperphagia and dysregulated appetite 135
White adipose tissue formation 5
Hypertension 42
Retention of sodium 42
Hyperuricemia 16
Decreased renal excretion of uric acid 16
Values are n. Bold numbers indicate the total number of proteins implicated in the general condition, later dissected by more specific motives. *Number of proteins implicated in each mechanism.
established ( Table 1) . The efficacy analysis identified the 3 following complementary strategies: 1) Consider sodium/glucose cotransporter 2, Na(þ)/glucose cotransporter 2 (SGLT2); 2) consider sodium/ hydrogen exchangers 1 and 3 (NHE1 and NHE3); and 3) considering empagliflozin bioflags; those proteins known to be modulated by the drug ( Table 2) . 2) Considering NHE1 and NHE3 as effectors, 2 conditions appear to be highly related (>75%) to empagliflozin's complete target profile:
ANN EVALUATES THE RELATIONSHIPS AMONG PROTEIN SETS INSIDE THE NETWORK, PROVIDING
Hypertension: retention of sodium is the main motive identified, with a predictive score of 80%.
HF: heart hypertrophy and cardiomyocyte cell death are the main motives identified, with a predictive score of 75.6%.
3) Three conditions appear to be highly related (>75%) to empagliflozin's bioflags:
Hyperuricemia: decreased renal excretion of uric acid is the motive most related to empagliflozin, with 77% of predictive score.
Obesity: the most related motives are hyperphagia and dysregulated appetite and white adipose tissue formation.
HF: the most related motives are energyinefficient myocardial fuel metabolism, oxidative stress, and inflammation.
NHE1 IS RESPONSIBLE FOR THE CARDIAC EFFECTS OF EMPAGLIFLOZIN IN HFrEF WITH OR WITHOUT
DM. By using the differentially expressed proteins found to be related to HF and the specific motives affected during the pharmacological treatment, the mathematical models determined the molecular mechanisms involved in the heart-focused beneficial effects of empagliflozin relative to heart failure in DM and non-DM patients.
The most robust MoA identified in this study involved the cardiac sodium/hydrogen exchanger 1 (NHE1) with 94.7% accuracy ( Figure 2 , Supplemental Table 3 ), which was similar for DM and non-DM patients, indicating a DM-independent mechanism (Table 3) . This approach describes mainly the mitigation of cell death but also the prevention of heart hypertrophy and the improvement upon an inefficient myocardial fuel metabolism as the potential heart-mediated mechanisms by which empagliflozin may counteract heart failure. Iborra-Egea et al.
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DISCUSSION
The EMPA-REG OUTCOME trial reported that empagliflozin exerted cardiovascular benefits which did not depend on its effects on blood glucose. This observation led to the hypothesis that empagliflozin exerted an effect on the myocardium independent of its inhibition of SGLT2 in the kidneys, thereby benefiting HF patients (6) . The exact mechanism remains unknown, but it was postulated to have a direct action on the heart. The present study used artificial intelligence and machine learning, further validated in an in vivo animal model, to investigate whether empagliflozin could exert direct effects on the heart and whether these effects were the same for patients with and without DM.
This study has 2 main findings. First, these results validate the fact that empagliflozin interacts with the cardiac Na þ /H þ exchanger NHE1 directly and identifies a mechanistic pathway acting primarily by reducing cardiomyocyte cell death, the main effector of its cardioprotective effects. Indeed, the activity of cardiac NHE1 seems to be increased in HFrEF patients, and previous data in experimental models (17) (18) (19) (20) (21) showed that NHE1 inhibition attenuated cardiomyocyte injury, remodeling, systolic dysfunction, and ultimately HF. Second, these data suggest that ANOVA followed by Tukey post hoc test was used for normally distributed data, whereas Kruskal-Wallis followed by Mann-Whitney U test was used for non-normally distributed data. Abbreviations as in Figure 2 .
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